Aldeyra Therapeutics Dirección
Dirección controles de criterios 2/4
El CEO de Aldeyra Therapeutics' es Todd Brady , nombrado en Jan 2012, tiene una permanencia de 12.42 años. compensación anual total es $3.68M, compuesta por 15.8% salario y 84.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.94% de las acciones de la empresa, por valor de $4.25M. La antigüedad media del equipo directivo y de la junta directiva es de 3.4 años y 10.8 años, respectivamente.
Información clave
Todd Brady
Chief Executive Officer (CEO)
US$3.7m
Compensación total
| Porcentaje del salario del CEO | 15.8% |
| Permanencia del CEO | 12.4yrs |
| Participación del CEO | 1.9% |
| Permanencia media de la dirección | 3.4yrs |
| Promedio de permanencia en la Junta Directiva | 10.8yrs |
Actualizaciones recientes de la dirección
Recent updates
Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?
Jun 21
Is Aldeyra Therapeutics (NASDAQ:ALDX) Weighed On By Its Debt Load?
Feb 16Health Check: How Prudently Does Aldeyra Therapeutics (NASDAQ:ALDX) Use Debt?
Nov 06Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?
Mar 26Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?
Nov 19Aldeyra Therapeutics on track to submit new drug application for dry eye disease treatment
Sep 14Aldeyra Therapeutics: Poised For Dry Eye Disease Therapy Monetization
Aug 04Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Debt In A Risky Way?
Aug 03Aldeyra says trial for dry eye disease candidate reached key goals
Jul 12Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?
Apr 19Aldeyra Therapeutics Stock: An Undervalued Biotech With Upcoming Catalysts
Feb 17Aldeyra Therapeutics: Tranquility's Setback Creates A Buying Opportunity If You Believe In Reproxalap
Dec 23Does Aldeyra Therapeutics (NASDAQ:ALDX) Have A Healthy Balance Sheet?
Dec 22Revisiting Aldeyra Therapeutics
Sep 29Aldeyra Therapeutics: A New Approach To Ocular Inflammatory Diseases With Impressive Clinical Data
Jun 01Aldeyra Therapeutics EPS beats by $0.01
May 06Aldeyra's conjunctivitis treatment meets late-stage study main goals
Apr 27How Many Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Shares Did Insiders Buy, In The Last Year?
Feb 23Aldeyra announces reproxalap's late-stage dry eye disease trial design
Feb 04Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$30m |
| Dec 31 2023 | US$4m | US$581k | -US$38m |
| Sep 30 2023 | n/a | n/a | -US$46m |
| Jun 30 2023 | n/a | n/a | -US$52m |
| Mar 31 2023 | n/a | n/a | -US$61m |
| Dec 31 2022 | US$3m | US$559k | -US$62m |
| Sep 30 2022 | n/a | n/a | -US$65m |
| Jun 30 2022 | n/a | n/a | -US$66m |
| Mar 31 2022 | n/a | n/a | -US$63m |
| Dec 31 2021 | US$3m | US$547k | -US$58m |
| Sep 30 2021 | n/a | n/a | -US$53m |
| Jun 30 2021 | n/a | n/a | -US$46m |
| Mar 31 2021 | n/a | n/a | -US$39m |
| Dec 31 2020 | US$2m | US$544k | -US$38m |
| Sep 30 2020 | n/a | n/a | -US$39m |
| Jun 30 2020 | n/a | n/a | -US$49m |
| Mar 31 2020 | n/a | n/a | -US$55m |
| Dec 31 2019 | US$4m | US$523k | -US$61m |
| Sep 30 2019 | n/a | n/a | -US$58m |
| Jun 30 2019 | n/a | n/a | -US$50m |
| Mar 31 2019 | n/a | n/a | -US$46m |
| Dec 31 2018 | US$3m | US$506k | -US$39m |
| Sep 30 2018 | n/a | n/a | -US$35m |
| Jun 30 2018 | n/a | n/a | -US$29m |
| Mar 31 2018 | n/a | n/a | -US$26m |
| Dec 31 2017 | US$2m | US$473k | -US$22m |
Compensación vs. Mercado: La compensación total de Todd($USD3.68M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD1.58M).
Compensación vs. Ingresos: La compensación de Todd ha aumentado mientras la empresa no es rentable.
CEO
Todd Brady (52 yo)
12.4yrs
Permanencia
US$3,684,651
Compensación
Dr. Todd C. Brady, M.D., Ph D., served as a Director at F-star Therapeutics, Inc from November 20, 2020 to March 2023. He has been the Chief Executive Officer and President of Aldeyra Therapeutics, Inc. si...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Director | 12.4yrs | US$3.68m | 1.94% $ 3.9m | |
| Senior VP of Finance | 2.1yrs | US$974.07k | 0.060% $ 121.0k | |
| Chief Development Officer | 3.4yrs | US$1.59m | 0.14% $ 277.5k | |
| Head of Investor Relations | no data | sin datos | sin datos |
3.4yrs
Permanencia media
52yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de ALDX se considera experimentado (3.4 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Director | 19.4yrs | US$3.68m | 1.94% $ 3.9m | |
| Independent Chair of the Board | 7.8yrs | US$221.98k | 0.21% $ 425.0k | |
| Independent Director | 14yrs | US$190.40k | 0.048% $ 96.0k | |
| Independent Director | 15.1yrs | US$194.07k | 0.025% $ 50.4k | |
| Independent Director | 10.7yrs | US$195.66k | 0.040% $ 81.5k | |
| Independent Director | 11yrs | US$174.22k | 0.027% $ 53.9k | |
| Member of Retina Segment Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Anterior Segment Scientific Advisory Board | 4.4yrs | sin datos | sin datos | |
| Member of Anterior Segment Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 4.4yrs | US$174.22k | 0% $ 0 | |
| Member of Anterior Segment Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Anterior Segment Scientific Advisory Board | no data | sin datos | sin datos |
10.8yrs
Permanencia media
65yo
Promedio de edad
Junta con experiencia: Los miembros de la junta directiva de ALDX son experimentados ( 10.8 años antigüedad media).